Life Sciences Mergers and Acquisitions

Evaluating, Negotiating, and Completing Successful Deals

mercredi 12 mars 2008

À propos de

As pharma companies compete to develop robust pipelines, M&A activity is a prime concern for the business. Because of the increased price and complexity of collaborations, life sciences companies are using M&As to invest in the next wave of new discoveries, new opportunities, and new partnerships.

Before entering into any M&A transaction, companies need to evaluate the business goals of the transaction, look at market trends, and determine whether an M&A is the most effective course of action for achieving their corporate objectives. Smaller companies must take certain steps to position themselves as attractive acquisition targets.

Negotiating M&As in the life sciences arena is significantly different from deals in other industries. For life sciences companies, you need to know how to handle the unique challenges in conducting an accurate due diligence on a pipeline and valuing the assets.

In addition, you need to know how to resolve any regulatory issues or antitrust obstacles that arise during the negotiation.

Closing the deal is just the beginning of the process. Structuring a workable integration plan is essential to a successful transaction.

With the needs of your company in mind, ACI has developed this publication from the 2nd Annual Life Sciences Mergers and Acquisitions conference.

A stellar faculty of industry leaders will provide you with the best practices for evaluating, negotiating, and closing successful M&A deals in the life sciences industries.

Contenus & Apports

À propos de

As pharma companies compete to develop robust pipelines, M&A activity is a prime concern for the business. Because of the increased price and complexity of collaborations, life sciences companies are using M&As to invest in the next wave of new discoveries, new opportunities, and new partnerships.

Before entering into any M&A transaction, companies need to evaluate the business goals of the transaction, look at market trends, and determine whether an M&A is the most effective course of action for achieving their corporate objectives. Smaller companies must take certain steps to position themselves as attractive acquisition targets.

Negotiating M&As in the life sciences arena is significantly different from deals in other industries. For life sciences companies, you need to know how to handle the unique challenges in conducting an accurate due diligence on a pipeline and valuing the assets.

In addition, you need to know how to resolve any regulatory issues or antitrust obstacles that arise during the negotiation.

Closing the deal is just the beginning of the process. Structuring a workable integration plan is essential to a successful transaction.

With the needs of your company in mind, ACI has developed this publication from the 2nd Annual Life Sciences Mergers and Acquisitions conference.

A stellar faculty of industry leaders will provide you with the best practices for evaluating, negotiating, and closing successful M&A deals in the life sciences industries.

Contenus & Apports

CURRENT TRENDS – MERGERS & ACQUISITIONS
Michael McCully, Recombinant Capital (Walnut Creek, CA)

DEAL OR NO DEAL? WHAT YOUR COMPANY MUST DO BEFORE ENTERING INTO ANY M&A NEGOTIATION
Winston K.C. Lam, Schering-Plough Corporation (Kenilworth, NJ)
Randall B. Sunberg, Morgan, Lewis & Bockius LLP (Princeton, NJ)

ALIGNING THE GOALS AND CHALLENGES OF ALL PARTIES TO CREATE A COMMON VISION FOR THE COMBINED BUSINESS
Jeffrey L. Wade, Lexicon Pharmaceuticals, Inc. (The Woodlands, TX)

POSITIONING A BIOTECH COMPANY TO BE AN ATTRACTIVE ACQUISITION TARGET
Thomas Gunning, EMD Serono, Inc. (Rockland, MA)

POSITIONING A BIOTECH COMPANY TO BE AN ATTRACTIVE ACQUISITION TARGET
Tom E. Repke, McDermott Will & Emery (Washington, DC)

BRIDGING THE VALUE GAP BETWEEN BUYER AND SELLER: FINDING THE “RIGHT” VALUATION AND CLOSING THE DEAL
Glen Y. Sato, Cooley Godward Kronish LLP (Palo Alto, CA)
Matthew N. Murray, Ph.D., New York Private Equity (New York, NY)

ESSENTIAL COMPONENTS OF LIFE SCIENCES DUE DILIGENCE
Gerald E. Quirk, Infinity Pharmaceuticals, Inc. (Cambridge, MA)
Catherine J. Dargan, Covington & Burling LLP (Washington, DC)

UNCOVERING AND RESOLVING HIDDEN CONCERNS, RISKS, AND RED FLAGS THAT ARISE DURING THE DUE DILIGENCE REVIEW
Sean P. Wajert, Dechert LLP (Philadelphia, PA)

MERGERS IN THE LIFE SCIENCES: HOW TO GET YOUR DEAL THROUGH THE ANTITRUST REVIEW PROCESS
Matthew J. Reilly, Federal Trade Commission (Washington, DC)
John E. Scribner, Weil, Gotshal & Manges LLP (Washington, DC)

CRITICAL REGULATORY CONCERNS THAT MUST BE ADDRESSED IN A LIFE SCIENCES M&A
Stephen Paul Mahinka, Morgan, Lewis & Bockius LLP (Washington, DC)

OVERCOMING THE CHALLENGES OF STRUCTURING A GLOBAL M&A TRANSACTION
James Farrington, Wiggin & Dana LLP (Stamford, CT)

HYBRID TRANSACTIONS
Kenneth A. Clark, Wilson Sonsini Goodrich & Rosati (Palo Alto, CA)



DOCUMENT TYPES: PRESENTATIONS AVAILABLE: 0